Mutation-driven cancers are without a doubt, one of the major medical challenges of the current century. Over the past decade, intense comprehensive sequencing has revealed the genomic, transcriptomic, and epigenetic landscapes in cancer, leading to the investigation of novel tailored therapeutic approaches. Mutation-induced hyperactivated signaling plays a significant role in cancer and is now proposed as a specific potential druggable target.
Despite the revolutionary advances of both immuno- and targeted- therapies in cancer management, innate and acquired resistance almost universally develop. Understanding how cancers escape immune surveillance and adapt under therapeutic pressure is fundamental to identifying effective therapeutic strategies.
In this context, next-generation therapies should exploit cancer cell vulnerabilities. Therapeutic strategies should i) be rationalized based on specific cancer biology, ii) assess therapy impact on tumor killing while conserving or boosting the immune system, and iii) favor well-defined regimens supported by preclinical proof of concept studies. Immunotherapies, small molecules, and other approaches are welcomed in combination or as single-agent therapy.
A complementary area of interest is the strategy to overcome acquired resistance to current therapies. By rewiring the immune system, combining therapeutics to re-sensitize tumor cells, or targeting the cause of resistance, we may revolutionize the era of precision medicine.
This special issue aims to feature primary research on innovative therapeutic strategies to defeat mutation-driven cancers and will welcome original articles and reviews. Potential topics include but are not limited to:
• Targeted therapy/small molecules
• Immunotherapy
• Cell therapy
• Combinatorial approaches
• Rationalized therapeutic regimens
• Preclinical proof of concept validating innovative therapy
• Defining drug mechanism of action
• Overcoming or forestalling resistance
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Mutation-driven cancers are without a doubt, one of the major medical challenges of the current century. Over the past decade, intense comprehensive sequencing has revealed the genomic, transcriptomic, and epigenetic landscapes in cancer, leading to the investigation of novel tailored therapeutic approaches. Mutation-induced hyperactivated signaling plays a significant role in cancer and is now proposed as a specific potential druggable target.
Despite the revolutionary advances of both immuno- and targeted- therapies in cancer management, innate and acquired resistance almost universally develop. Understanding how cancers escape immune surveillance and adapt under therapeutic pressure is fundamental to identifying effective therapeutic strategies.
In this context, next-generation therapies should exploit cancer cell vulnerabilities. Therapeutic strategies should i) be rationalized based on specific cancer biology, ii) assess therapy impact on tumor killing while conserving or boosting the immune system, and iii) favor well-defined regimens supported by preclinical proof of concept studies. Immunotherapies, small molecules, and other approaches are welcomed in combination or as single-agent therapy.
A complementary area of interest is the strategy to overcome acquired resistance to current therapies. By rewiring the immune system, combining therapeutics to re-sensitize tumor cells, or targeting the cause of resistance, we may revolutionize the era of precision medicine.
This special issue aims to feature primary research on innovative therapeutic strategies to defeat mutation-driven cancers and will welcome original articles and reviews. Potential topics include but are not limited to:
• Targeted therapy/small molecules
• Immunotherapy
• Cell therapy
• Combinatorial approaches
• Rationalized therapeutic regimens
• Preclinical proof of concept validating innovative therapy
• Defining drug mechanism of action
• Overcoming or forestalling resistance
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
